DÜSSELDORF, Germany—Hanmi Science, the holding company of South Korea's Hanmi Group, is poised to intensify its push into the international surgical hemostatic agent market. The company announced its plans to debut three key surgical hemostasis products—Oozefix, Tableau Wax, and ActiClot—at MEDICA 2025, the world's largest medical device exhibition, scheduled to take place from November 17-20 in Düsseldorf, Germany. These products, developed by Terracion Biomedicals, are marketed globally under exclusive overseas distribution rights held by Hanmi Science.
The global market for hemostatic agents, critical for managing surgical bleeding and minimizing complications, is experiencing robust growth, driven by an increasing volume of surgical procedures and a growing demand for advanced, effective bleeding control solutions. Hanmi Science's participation in MEDICA 2025 is a strategic maneuver to capitalize on this expansion, leveraging the exhibition's international platform to attract global partners and showcase the technological prowess of South Korean medical devices.
Innovative Hemostasis Solutions
The trio of hemostatic agents represents a specialized approach to surgical bleeding control, each designed for distinct clinical applications:
Oozefix is an absorbable, powdered hemostat intended for use following initial hemostasis to control capillary, venous, or arteriolar oozing. Its powder format allows for easy application to diffuse bleeding surfaces, enhancing its utility in a variety of complex surgical fields.
Tableau Wax is a poloxamer-based absorbable hemostat. Unlike traditional agents, it forms a protective barrier over bone surfaces, maintaining a sealing effect crucial in various surgical settings, including cardiovascular surgery (CS), orthopedic surgery (OS), and neurosurgery (NS). This unique mechanism addresses the specific challenge of achieving hemostasis in bony sites.
ActiClot is an active hemostatic agent that combines starch with thrombin. The integration of thrombin, a natural clotting factor, accelerates clot formation. Crucially, ActiClot is engineered for rapid absorption, biodegrading within the body in approximately three days, a feature that significantly minimizes the risk of foreign body reactions or inflammation.
Strategic Global Expansion
Hanmi Science views the MEDICA exhibition as a pivotal moment for aggressive international expansion. The company's strategy involves actively seeking out partnerships with distributors and hospital stakeholders across key international markets, including Europe, the Middle East, and Asia.
A company representative emphasized the strategic importance of this global launch, stating, "Our presence at MEDICA will be an essential catalyst for promoting the excellence of South Korean medical devices on the world stage. We aim to strengthen Hanmi Science's position within the global healthcare industry and continuously broaden our overseas business footprint, beginning with these three specialized hemostatic agents."
By showcasing Oozefix, Tableau Wax, and ActiClot, Hanmi Science intends to highlight both the clinical efficacy and technical superiority of the products to a vast international audience of medical professionals. The successful introduction and subsequent market penetration of these hemostats will be a key indicator of the company's ability to transition from a regional player to a significant force in the highly competitive global medical device sector. This strategic move aligns with a broader corporate goal of establishing a sustainable, long-term international business presence beyond its traditional pharmaceutical focus.
[Copyright (c) Global Economic Times. All Rights Reserved.]
